PubMed:23280345
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-111 | Sentence | denotes | Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. |
| T2 | 112-260 | Sentence | denotes | Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that mainly causes the synovial joint inflammation and cartilage destruction. |
| T3 | 261-391 | Sentence | denotes | Both interleukin-1β (IL-1β) and Interleukin-17 (IL-17) are important proinflammatory cytokines involved in the pathogenesis of RA. |
| T4 | 392-572 | Sentence | denotes | We investigated whether combination therapy with IL-1β and IL-17A antibodies would generate the potential for synergistic effects on a collagen-induced arthritis (CIA) mouse model. |
| T5 | 573-689 | Sentence | denotes | Mice with CIA were subcutaneously injected with humanized IL-1β antibody, IL-17A antibody, or combination treatment. |
| T6 | 690-877 | Sentence | denotes | The effects of treatment were determined by arthritis severity score, histological damage and bone destruction, autoreactive humoral and cellular immune responses and cytokine production. |
| T7 | 878-1016 | Sentence | denotes | Treatment with IL-1β antibody or IL-17A antibody alone resulted in beneficial effects on clinical and histological parameters of CIA mice. |
| T8 | 1017-1372 | Sentence | denotes | Compared with the single antibody treatments, the combination therapy resulted in a more significant effect in alleviating the severity of arthritis by preventing bone damage and cartilage destruction, reducing humoral and cellular immune responses, and down-regulating the expression of IL-1β, IL-6, IL-17A, IFN-γ, RANKL and MMP-3 in inflammatory tissue. |
| T9 | 1373-1591 | Sentence | denotes | In conclusion, combination treatment with humanized IL-1β and IL-17A antibodies demonstrates synergistic beneficial effects for preventing joint inflammation and cartilage destruction and bone damage in CIA mice model. |
| T10 | 1592-1734 | Sentence | denotes | These studies also provide evidence that combination with IL-1β and IL-17A antibodies may lead to a new combinatorial therapy for RA patients. |
| T1 | 0-111 | Sentence | denotes | Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. |
| T2 | 112-260 | Sentence | denotes | Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that mainly causes the synovial joint inflammation and cartilage destruction. |
| T3 | 261-391 | Sentence | denotes | Both interleukin-1β (IL-1β) and Interleukin-17 (IL-17) are important proinflammatory cytokines involved in the pathogenesis of RA. |
| T4 | 392-572 | Sentence | denotes | We investigated whether combination therapy with IL-1β and IL-17A antibodies would generate the potential for synergistic effects on a collagen-induced arthritis (CIA) mouse model. |
| T5 | 573-689 | Sentence | denotes | Mice with CIA were subcutaneously injected with humanized IL-1β antibody, IL-17A antibody, or combination treatment. |
| T6 | 690-877 | Sentence | denotes | The effects of treatment were determined by arthritis severity score, histological damage and bone destruction, autoreactive humoral and cellular immune responses and cytokine production. |
| T7 | 878-1016 | Sentence | denotes | Treatment with IL-1β antibody or IL-17A antibody alone resulted in beneficial effects on clinical and histological parameters of CIA mice. |
| T8 | 1017-1372 | Sentence | denotes | Compared with the single antibody treatments, the combination therapy resulted in a more significant effect in alleviating the severity of arthritis by preventing bone damage and cartilage destruction, reducing humoral and cellular immune responses, and down-regulating the expression of IL-1β, IL-6, IL-17A, IFN-γ, RANKL and MMP-3 in inflammatory tissue. |
| T9 | 1373-1591 | Sentence | denotes | In conclusion, combination treatment with humanized IL-1β and IL-17A antibodies demonstrates synergistic beneficial effects for preventing joint inflammation and cartilage destruction and bone damage in CIA mice model. |
| T10 | 1592-1734 | Sentence | denotes | These studies also provide evidence that combination with IL-1β and IL-17A antibodies may lead to a new combinatorial therapy for RA patients. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 266-280 | gene:3553 | denotes | interleukin-1β |
| T1 | 388-390 | disease:C0003873 | denotes | RA |
| T2 | 441-446 | gene:3553 | denotes | IL-1β |
| T3 | 527-553 | disease:C0971858 | denotes | collagen-induced arthritis |
| T4 | 441-446 | gene:3553 | denotes | IL-1β |
| T5 | 555-558 | disease:C0971858 | denotes | CIA |
| T6 | 451-457 | gene:3605 | denotes | IL-17A |
| T7 | 527-553 | disease:C0971858 | denotes | collagen-induced arthritis |
| T8 | 451-457 | gene:3605 | denotes | IL-17A |
| T9 | 555-558 | disease:C0971858 | denotes | CIA |
| T10 | 1435-1441 | gene:3605 | denotes | IL-17A |
| T11 | 1576-1579 | disease:C0971858 | denotes | CIA |
| T12 | 1425-1430 | gene:3553 | denotes | IL-1β |
| T13 | 1576-1579 | disease:C0971858 | denotes | CIA |
| T14 | 1435-1441 | gene:3605 | denotes | IL-17A |
| T15 | 1512-1530 | disease:C0003864 | denotes | joint inflammation |
| T16 | 1425-1430 | gene:3553 | denotes | IL-1β |
| T17 | 1512-1530 | disease:C0003864 | denotes | joint inflammation |
| T18 | 1650-1655 | gene:3553 | denotes | IL-1β |
| T19 | 1722-1724 | disease:C0003873 | denotes | RA |
| T20 | 1660-1666 | gene:3605 | denotes | IL-17A |
| T21 | 1722-1724 | disease:C0003873 | denotes | RA |
| R1 | T0 | T1 | associated_with | interleukin-1β,RA |
| R2 | T2 | T3 | associated_with | IL-1β,collagen-induced arthritis |
| R3 | T4 | T5 | associated_with | IL-1β,CIA |
| R4 | T6 | T7 | associated_with | IL-17A,collagen-induced arthritis |
| R5 | T8 | T9 | associated_with | IL-17A,CIA |
| R6 | T10 | T11 | associated_with | IL-17A,CIA |
| R7 | T12 | T13 | associated_with | IL-1β,CIA |
| R8 | T14 | T15 | associated_with | IL-17A,joint inflammation |
| R9 | T16 | T17 | associated_with | IL-1β,joint inflammation |
| R10 | T18 | T19 | associated_with | IL-1β,RA |
| R11 | T20 | T21 | associated_with | IL-17A,RA |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_23280345_1_0 | 112-132 | expanded | denotes | Rheumatoid arthritis |
| SS2_23280345_1_0 | 134-136 | abbr | denotes | RA |
| SS1_23280345_2_0 | 266-280 | expanded | denotes | interleukin-1β |
| SS2_23280345_2_0 | 282-287 | abbr | denotes | IL-1β |
| SS1_23280345_2_1 | 293-307 | expanded | denotes | Interleukin-17 |
| SS2_23280345_2_1 | 309-314 | abbr | denotes | IL-17 |
| SS1_23280345_3_0 | 527-553 | expanded | denotes | collagen-induced arthritis |
| SS2_23280345_3_0 | 555-558 | abbr | denotes | CIA |
| AE1_23280345_1_0 | SS1_23280345_1_0 | SS2_23280345_1_0 | abbreviatedTo | Rheumatoid arthritis,RA |
| AE1_23280345_2_0 | SS1_23280345_2_0 | SS2_23280345_2_0 | abbreviatedTo | interleukin-1β,IL-1β |
| AE1_23280345_2_1 | SS1_23280345_2_1 | SS2_23280345_2_1 | abbreviatedTo | Interleukin-17,IL-17 |
| AE1_23280345_3_0 | SS1_23280345_3_0 | SS2_23280345_3_0 | abbreviatedTo | collagen-induced arthritis,CIA |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 112-132 | HP_0001370 | denotes | Rheumatoid arthritis |
| T2 | 123-132 | HP_0001369 | denotes | arthritis |
| T3 | 151-161 | HP_0002960 | denotes | autoimmune |
| T4 | 238-259 | HP_0100773 | denotes | cartilage destruction |
| T5 | 544-553 | HP_0001369 | denotes | arthritis |
| T6 | 734-743 | HP_0001369 | denotes | arthritis |
| T7 | 1156-1165 | HP_0001369 | denotes | arthritis |
| T8 | 1196-1217 | HP_0100773 | denotes | cartilage destruction |
| T9 | 1535-1556 | HP_0100773 | denotes | cartilage destruction |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 23280345-0#23#37#gene3553 | 23-37 | gene3553 | denotes | interleukin-1β |
| 23280345-0#42#57#gene3605 | 42-57 | gene3605 | denotes | interleukin-17A |
| 23280345-0#89#98#diseaseC0003864 | 89-98 | diseaseC0003864 | denotes | arthritis |
| 23280345-2#5#19#gene3553 | 266-280 | gene3553 | denotes | interleukin-1β |
| 23280345-2#21#26#gene3553 | 282-287 | gene3553 | denotes | IL-1β |
| 23280345-2#127#129#diseaseC0003873 | 388-390 | diseaseC0003873 | denotes | RA |
| 23280345-7#326#331#gene4314 | 1343-1348 | gene4314 | denotes | MMP-3 |
| 23280345-7#139#148#diseaseC0003864 | 1156-1165 | diseaseC0003864 | denotes | arthritis |
| 23280345-9#68#74#gene3605 | 1660-1666 | gene3605 | denotes | IL-17A |
| 23280345-9#130#132#diseaseC0003873 | 1722-1724 | diseaseC0003873 | denotes | RA |
| 23#37#gene355389#98#diseaseC0003864 | 23280345-0#23#37#gene3553 | 23280345-0#89#98#diseaseC0003864 | associated_with | interleukin-1β,arthritis |
| 42#57#gene360589#98#diseaseC0003864 | 23280345-0#42#57#gene3605 | 23280345-0#89#98#diseaseC0003864 | associated_with | interleukin-17A,arthritis |
| 5#19#gene3553127#129#diseaseC0003873 | 23280345-2#5#19#gene3553 | 23280345-2#127#129#diseaseC0003873 | associated_with | interleukin-1β,RA |
| 21#26#gene3553127#129#diseaseC0003873 | 23280345-2#21#26#gene3553 | 23280345-2#127#129#diseaseC0003873 | associated_with | IL-1β,RA |
| 326#331#gene4314139#148#diseaseC0003864 | 23280345-7#326#331#gene4314 | 23280345-7#139#148#diseaseC0003864 | associated_with | MMP-3,arthritis |
| 68#74#gene3605130#132#diseaseC0003873 | 23280345-9#68#74#gene3605 | 23280345-9#130#132#diseaseC0003873 | associated_with | IL-17A,RA |